HK1165413A1 - 4-isopropylphenyl glucitol compounds as sglt1 inhibitors 4- sglt1 - Google Patents

4-isopropylphenyl glucitol compounds as sglt1 inhibitors 4- sglt1

Info

Publication number
HK1165413A1
HK1165413A1 HK12105940.6A HK12105940A HK1165413A1 HK 1165413 A1 HK1165413 A1 HK 1165413A1 HK 12105940 A HK12105940 A HK 12105940A HK 1165413 A1 HK1165413 A1 HK 1165413A1
Authority
HK
Hong Kong
Prior art keywords
sglt1
inhibitors
glucitol compounds
isopropylphenyl glucitol
isopropylphenyl
Prior art date
Application number
HK12105940.6A
Other languages
English (en)
Chinese (zh)
Inventor
柿沼浩行
小橋陽平
長南具通
大井隆宏
鹽澤史康
岩田由紀
川部憲
Original Assignee
大正制藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大正制藥株式會社 filed Critical 大正制藥株式會社
Publication of HK1165413A1 publication Critical patent/HK1165413A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • C07D309/12Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
HK12105940.6A 2009-02-23 2012-06-18 4-isopropylphenyl glucitol compounds as sglt1 inhibitors 4- sglt1 HK1165413A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009038776 2009-02-23
PCT/JP2010/053187 WO2010095768A1 (en) 2009-02-23 2010-02-23 4 -isopropylphenyl glucitol compounds as sgltl inhibitors

Publications (1)

Publication Number Publication Date
HK1165413A1 true HK1165413A1 (en) 2012-10-05

Family

ID=42101407

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105940.6A HK1165413A1 (en) 2009-02-23 2012-06-18 4-isopropylphenyl glucitol compounds as sglt1 inhibitors 4- sglt1

Country Status (22)

Country Link
US (1) US8466113B2 (ru)
EP (1) EP2398786B1 (ru)
JP (1) JP5505741B2 (ru)
KR (1) KR101653853B1 (ru)
CN (1) CN102414191B (ru)
AR (1) AR075582A1 (ru)
AU (1) AU2010216634B2 (ru)
BR (1) BRPI1008653A2 (ru)
CA (1) CA2752212C (ru)
CL (1) CL2011002041A1 (ru)
CO (1) CO6362001A2 (ru)
ES (1) ES2397086T3 (ru)
HK (1) HK1165413A1 (ru)
IL (1) IL214727A0 (ru)
MX (1) MX2011008839A (ru)
MY (1) MY155658A (ru)
PE (1) PE20120648A1 (ru)
RU (1) RU2518896C2 (ru)
SG (1) SG173801A1 (ru)
TW (1) TWI460187B (ru)
WO (1) WO2010095768A1 (ru)
ZA (1) ZA201105928B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5817317B2 (ja) * 2010-08-20 2015-11-18 大正製薬株式会社 4−イソプロピルフェニルグルシトール化合物を有効成分として含有することを特徴とする糖尿病の予防又は治療剤
WO2012023600A1 (ja) * 2010-08-20 2012-02-23 大正製薬株式会社 4-イソプロピル-6-メトキシフェニル グルシトール化合物
AU2011291709B2 (en) 2010-08-20 2014-03-27 Taisho Pharmaceutical Co., Ltd. Crystal form of 4-isopropylphenyl glucitol compound and process for production thereof
JP2014530186A (ja) 2011-09-13 2014-11-17 パナセア バイオテック リミテッド 新規sglt阻害剤
UA113086C2 (xx) 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) * 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
US10022389B2 (en) * 2013-02-04 2018-07-17 Taisho Pharmaceutical Co., Ltd. Prophylactic or therapeutic drug for constipation
AR098670A1 (es) 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
JP2019142774A (ja) * 2016-06-20 2019-08-29 大正製薬株式会社 腸内環境改善剤
CN110066302B (zh) * 2018-01-23 2022-12-27 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其用途
US11186602B2 (en) 2018-01-31 2021-11-30 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivative and use thereof
CN108610385A (zh) * 2018-04-23 2018-10-02 中国科学院成都生物研究所 一种钠-葡萄糖协同转运蛋白1抑制剂的药物用途
CN110117300A (zh) * 2018-04-23 2019-08-13 中国科学院成都生物研究所 包含钠-葡萄糖协同转运蛋白1抑制剂的药物用途
CN113825750B (zh) * 2019-03-29 2022-07-12 南京明德新药研发有限公司 作为sglt1抑制剂的葡糖苷类衍生物及其应用
EP3997079A4 (en) * 2019-07-10 2023-03-01 Sunshine Lake Pharma Co., Ltd. GLUCOPYRANOSYL DERIVATIVES AND THEIR USES
CN114599643B (zh) * 2020-05-15 2023-04-14 上海喆邺生物科技有限公司 一种芳基葡糖苷衍生物
EP4119550A4 (en) * 2020-05-15 2023-07-12 Shanghai Zheye Biotechnology Co., Ltd. ARYLGLUCOSIDE DERIVATIVE AND USE THEREOF IN PHARMACEUTICALS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US7217697B2 (en) 2001-05-30 2007-05-15 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor
NZ538117A (en) 2002-08-08 2007-01-26 Kissei Pharmaceutical Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP4606876B2 (ja) 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
CA2507665A1 (en) 2002-12-04 2004-06-17 Kissei Pharmaceutical Co., Ltd. Preventive or remedy for diseases caused by hyperglycemia
KR101001848B1 (ko) * 2003-03-14 2010-12-17 고토부키 세이야쿠 가부시키가이샤 C-글리코시드 유도체 또는 이의 염, 및 이를 포함하는 의약 조성물
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
JP2009167104A (ja) * 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd フェニル5−チオグリコシド化合物
NZ573687A (en) * 2006-05-19 2010-10-29 Taisho Pharmaceutical Co Ltd C-phenyl glycitol compound for the treatment of diabetes

Also Published As

Publication number Publication date
CN102414191A (zh) 2012-04-11
AU2010216634A1 (en) 2011-09-22
CO6362001A2 (es) 2012-01-20
CL2011002041A1 (es) 2012-04-09
TW201040195A (en) 2010-11-16
KR20110121626A (ko) 2011-11-07
TWI460187B (zh) 2014-11-11
SG173801A1 (en) 2011-09-29
US20110306759A1 (en) 2011-12-15
JP5505741B2 (ja) 2014-05-28
AU2010216634B2 (en) 2014-07-10
JP2012518631A (ja) 2012-08-16
RU2011138962A (ru) 2013-03-27
EP2398786A1 (en) 2011-12-28
ES2397086T3 (es) 2013-03-04
MY155658A (en) 2015-11-13
RU2518896C2 (ru) 2014-06-10
US8466113B2 (en) 2013-06-18
PE20120648A1 (es) 2012-05-31
CA2752212C (en) 2016-08-16
CA2752212A1 (en) 2010-08-26
WO2010095768A1 (en) 2010-08-26
WO2010095768A8 (en) 2011-08-04
IL214727A0 (en) 2011-11-30
EP2398786B1 (en) 2012-12-12
MX2011008839A (es) 2011-09-28
AR075582A1 (es) 2011-04-20
KR101653853B1 (ko) 2016-09-02
BRPI1008653A2 (pt) 2016-03-08
CN102414191B (zh) 2014-04-16
ZA201105928B (en) 2012-11-28

Similar Documents

Publication Publication Date Title
HK1165413A1 (en) 4-isopropylphenyl glucitol compounds as sglt1 inhibitors 4- sglt1
HUS1700026I1 (hu) Tetraciklusos vegyület
HRP20181695T1 (hr) Kristalni oblik inhibitora benzilbenzena sglt2
IL238338A (en) Processes for preparing sglt2 inhibitors
EP2714032A4 (en) NEW DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS
EP2463280A4 (en) CHROME COMPOUND
HK1170241A1 (zh) 可用作 的抑制劑的化合物的製備方法
PL2393812T3 (pl) Podstawione spiroamidy jako modulatory B1R
EP2479171A4 (en) CHROME LINK
EP2447267A4 (en) CHROME COMPOUND
EP2607360A4 (en) COMPOUND 4-ISOPROPYL-6-METHOXYPHENYL GLUCITOL
EP2444401A4 (en) NEW IMIDAZOPYRIDINE COMPOUND
GB0915927D0 (en) Novel inhibitors
GB0914441D0 (en) Compound for therapy
GB0903080D0 (en) Compound for therapy
GB0901497D0 (en) Compound for therapy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230221